TREATING ATOPIC DERMATITIS: - The Dermatologist

Atopic Dermatitis — A Historical Review
23. Langan SM. Flares in Childhood Eczema. Skin Therapy Lett. 2009;14(8):4–5.
24. Dahl MV. Flare Factors and Atopic Dermatitis: The Role of Allergy. J Dermatol Sci. 1990;1(5):311–318.
25. Warshaw E, Lee G, Storrs FJ. Hand Dermatitis: A Review of Clinical Features, Therapeutic Options,
and Long-Term Outcomes. Am J Contact Dermat. 2003;14(3):119–137.
26. Meding B, Swanbeck G. Epidemiology of Different Types of Hand Eczema in an Industrial City. Acta
Derm Venereol. 1989;69(3):227–233.
27. Ingordo V, D'Andria G, D'Andria C. Adult-Onset Atopic Dermatitis in a Patch Test Population. Dermatology.
2003;206(3):197–203.
28. Thune P. Evaluation of the Hydration and the Water-Holding Capacity in Atopic Skin and So-Called
Dry Skin. Acta Derm Venereol. 1989;144(Suppl):133–135.
29. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in Atopic Dermatitis. J Allergy Clin Immunol.
2008;122(4):689–693.
30. Rawlings AV, Harding CR. Moisturization and Skin Barrier Function. Dermatol Ther. 2004;17(Suppl
1):43–48.
31. Proksch E, Folster-Holst R, Jensen JM. Skin Barrier Function, Epidermal Proliferation and Differentiation
in Eczema. J Dermatol Sci. 2006;43(3):159–169.
32. Jensen JM, Fölster-Holst R, Baranowsky A, et al. Impaired Sphingomyelinase Activity and Epidermal
Differentiation in Atopic Dermatitis. J Invest Dermatol. 2004;122(6):1423–1431.
33. Elias PM, Schmuth M. Abnormal Skin Barrier in the Etiopathogenesis of Atopic Dermatitis. Curr Opin
Allergy Clin Immunol. 2009;9(5):437–446.
34. Elias PM, Steinhoff M. "Outside-to-Inside" (and Now Back to "Outside") Pathogenic Mechanisms in
Atopic Dermatitis. J Invest Dermatol. 2008;128(5):1067–1070.
35. Henderson J, Northstone K, Lee SP, et al. The Burden of Disease Associated With Filaggrin Mutations:
A Population-Based, Longitudinal Birth Cohort Study. J Allergy Clin Immunol. 2008;121(4):872–877 e9.
36. Arikawa J, Ishibashi M, Kawashima M, et al. Decreased Levels of Sphingosine, a Natural Antimicrobial
Agent, May Be Associated With Vulnerability of the Stratum Corneum From Patients With Atopic Dermatitis
to Colonization by Staphylococcus aureus. J Invest Dermatol. 2002;119(2):433–439.
37. Imokawa G, Abe A, Jin K, et al. Decreased Level of Ceramides in Stratum Corneum of Atopic Dermatitis:
An Etiologic Factor in Atopic Dry Skin? J Invest Dermatol. 1991;96(4):523–526.
38. Product information [data on file]. Essen, Germany: Goldschmidt Personal Care.
39. Product information [data on file]. Norwalk, CT: Centerchem, Inc.
40. Elias PM. Physiologic Lipids for Barrier Repair in Dermatology, in Procedures in Cosmetic Dermatology.
In: Draelos ZD, ed. Cosmeceuticals. Philadelphia, PA: Elsevier; 2005.
41. Huang HC, Chang TM. Ceramide 1 and Ceramide 3 Act Synergistically on Skin Hydration and the
Transepidermal Water Loss of Sodium Lauryl Sulfate-Irritated Skin. Int J Dermatol. 2008;47(8):812–819.
42. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-Dominant Barrier Repair Lipids Alleviate Childhood
Atopic Dermatitis: Changes in Barrier Function Provide a Sensitive Indicator of Disease Activity. J Am Acad
Dermatol. 2002;47(2):198–208.
43. Draelos ZD. The Effect of Ceramide-Containing Skin Care Products on Eczema Resolution Duration.
Cutis. 2008;81(1):87–91.
44. Elias PM. Stratum Corneum Defensive Functions: An Integrated View. J Invest Dermatol. 2005;125(2):183–200.
45. Schroder JM, Harder J. Antimicrobial Skin Peptides and Proteins. Cell Mol Life Sci. 2006;63(4):469–486.
46. Braff MH, Di Nardo A, Gallo RL. Keratinocytes Store the Antimicrobial Peptide Cathelicidin in Lamellar
Bodies. J Invest Dermatol. 2005;124(2):394–400.
47. Schauber J, Gallo RL. Antimicrobial Peptides and the Skin Immune Defense System. J Allergy Clin Immunol.
2009;124(3 Suppl 2):R13–R18.
48. Morioka Y, Yamasaki K, Leung D, Gallo RL. Cathelicidin Antimicrobial Peptides Inhibit Hyaluronan-Induced
Cytokine Release and Modulate Chronic Allergic Dermatitis. J Immunol. 2008;181(6):3915–3222.
49. Di Nardo A, Braff MH, Taylor KR, et al. Cathelicidin Antimicrobial Peptides Block Dendritic Cell
TLR4 Activation and Allergic Contact Sensitization. J Immunol. 2007;178(3):1829–1834.
50. Ong PY, Ohtake T, Brandt C, et al. Endogenous Antimicrobial Peptides and Skin Infections in Atopic
Dermatitis. N Engl J Med. 2002. 347(15):1151–1160.
51. Hata TR, Kotol P, Jackson M, et al. Administration of Oral Vitamin D Induces Cathelicidin Production
in Atopic Individuals. J Allergy Clin Immunol. 2008;122(4):829–831.
52. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of Hyaluronan Released in Sterile Injury Involves
a Unique Receptor Complex Dependent on Toll-Like Receptor 4, CD44, and MD-2. J Biol Chem.
2007;282(25):18265–18275.
53. Gong JQ, Lin L, Lin T, et al. Skin Colonization by Staphylococcus aureus in Patients With Eczema and
Atopic Dermatitis and Relevant Combined Topical Therapy: A Double-Blind Multicentre Randomized
Controlled Trial. Br J Dermatol. 2006;155(4):680–687.
54. Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative Study of Staphylococci From the Skin
of Atopic Dermatitis Patients and From Healthy Subjects. Int J Dermatol. 1999;38(4):265–269.
55. Cogen AL, Yamasaki K, Sanchez KM, et al. Selective Antimicrobial Action Is Provided by Phenol-Soluble
Modulins Derived From Staphylococcus epidermidis, a Normal Resident of the Skin. J Invest Dermatol.
2010;130(1):192–200.
56. Jacob SE, Burk CJ, Connelly EA. Patch Testing: Another Steroid-Sparing Agent to Consider in Children.
Pediatr Dermatol. 2008;25(1):81–87.
57. Zug KA, McGinley-Smith D, Warshaw EM, et al. Contact Allergy in Children Referred for Patch Testing:
North American Contact Dermatitis Group Data, 2001-2004. Arch Dermatol. 2008;144(10):1329–1336.
58. Jacob SE, Stechschulte S. Eyelid Dermatitis Associated With Balsam of Peru Constituents: Benzoic Acid
and Benzyl Alcohol. Contact Dermatitis. 2008;58(2):111–112.
59. Nijhawen RI, Matiz C, Jacob SE. Contact Dermatitis: From Basics to Allergodromes. Pediatric Annals.
2009;38(2):99–108.
60. Militello G, Jacob SE, Crawford GH. Allergic Contact Dermatitis in Children. Curr Opin Pediatr.
2006;18(4):385–390.
61. Hanifin JM. Filaggrin Mutations and Allergic Contact Sensitization. J Invest Dermatol. 2008;128(6):1362–1364.
62. Penna G, Adorini L. 1 Alpha, 25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation,
and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. J Immunol.
2000;164(5):2405–2411.
63. Uehara M, Sawai T. A Longitudinal Study of Contact Sensitivity in Patients With Atopic Dermatitis.
Arch Dermatol. 1989;125(3):366–368.
64. Lobitz WC Jr., Honeyman JF, Winkler NW. Suppressed Cell-Mediated Immunity in Two Adults With
Atopic Dermatitis. Br J Dermatol. 1972;86(4):317–328.
65. Lammintausta K, Kalimo K, Fagerlund VL. Patch Test Reactions in Atopic Patients. Contact Dermatitis.
1992;26(4):234–240.
66. Belhadjali H, Mohamed M, Youssef M, et al. Contact Sensitization in Atopic Dermatitis: Results of a
Prospective Study of 89 Cases in Tunisia. Contact Dermatitis. 2008;58(3):188–189.
67. Oranje, A.P., et al., Immediate- and Delayed-Type Contact Hypersensitivity in Children Older Than 5
Years With Atopic Dermatitis: A Pilot Study Comparing Different Tests. Pediatr Dermatol. 1994;11(3):209–215.
68. Oda Y, Uchida Y, Moradian S, et al. Vitamin D Receptor and Coactivators SRC2 and 3 Regulate Epidermis-Specific
Sphingolipid Production and Permeability Barrier Formation. J Invest Dermatol.
2009;129(6):1367–1378.
69. Hong SP, Kim MJ, Jung MY, et al. Biopositive Effects of Low-Dose UVB on Epidermis: Coordinate
Upregulation of Antimicrobial Peptides and Permeability Barrier Reinforcement. J Invest Dermatol.
2008;128(12):2880–2887.
70. The Eczema Center. Rady Children’s Hospital website. Available at: http://eczemacenter.org/
eczema_center/index.htm. Accessed August 31, 2010.
71. Zirwas MJ. Contact Dermatology Symposium. in American Academy of Dermatology Annual Meeting.
2010. Miami, FL.
72. Thomas KS, Armstrong S, Avery A, et al. Randomised Controlled Trial of Short Bursts of a Potent Topical
Corticosteroid Versus Prolonged Use of a Mild Preparation for Children With Mild or Moderate Atopic
Eczema. BMJ. 2002;324(7340):768.
73. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al., The Management of Moderate to Severe Atopic
Dermatitis in Adults With Topical Fluticasone Propionate. The Netherlands Adult Atopic DermatitisStudy
Group. Br J Dermatol. 1999;140(6):1114–1121.
74. Hanifin JM, Gupta AK, Rajagopalan R. Intermittent Dosing of Fluticasone Propionate Cream for Reducing
the Risk of Relapse in Atopic Dermatitis Patients. Br J Dermatol. 2002;147(3):528–537.
75. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of Care for Atopic Dermatitis, Developed in Accordance
With the American Academy of Dermatology (AAD)/American Academy of Dermatology Association
"Administrative Regulations for Evidence-Based Clinical Practice Guidelines." J Am Acad Dermatol.
2004;50(3):391–404.
76. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-Induced Atrophy and Barrier Impairment
Measured by Non-Invasive Methods in Human Skin. Skin Res Technol. 2001;7(2):73–77.
77. Del Rosso J, Friedlander SF. Corticosteroids: Options in the Era of Steroid-Sparing Therapy. J Am Acad
Dermatol. 2005;53(1 Suppl 1):S50–S58.
78. Jacob SE, Steele T. Focus on the Non-T.R.U.E. Test Allergen — Corticosteroids. Skin & Aging.
2006;14(10):32–36.
79. Davis MDP, el-Azhary RA, Farmer SA. Results of patch testing to a corticosteroid series: A retrospective
review of 1188 patents during 6 years at Mayo Clinic. J Am Acad Dermatol. 2007;56(6):921–927.
80. Dunkel FG, Elsner P, Burg G. Contact Allegies to Topical Corticosteroids: 10 Cases of Contact Dermatitis.
Contact Dermatitis. 1991;25(2):97–103.
81. Rivara G, Tomb RR, Foussereau J. Allergic Contact Dermatitis From Topical Corticosteroids. Contact
Dermatitis. 1989;21(2):83–91.
82. Ellis C, Luger T, Abeck D, et al; ICCAD II Faculty. International Consensus Conference on Atopic Dermatitis
II (ICCAD II): Clinical Update and Current Treatment Strategies. Br J Dermatol. 2003;148(Suppl 63):3–10.
83. Shaw DW, Maibach HI, Eichenfield LF. Allergic Contact Dermatitis From Pimecrolimus in a Patient
With Tacrolimus Allergy. J Am Acad Dermatol. 2007;56(2):342–345.
84. Saitta P, Brancaccio R. Allergic Contact Dermatitis to Pimecrolimus. Contact Dermatitis. 2007;56(1):43–44.
85. FDA Approves MimyX Cream for the Treatment of Atopic Dermatitis. January 2006. Bnet website.
Available at: http://findarticles.com/p/articles/mi_m0PDG/is_1_5/ai_n16045491/?tag=content;col1(accessed.
Accessed August 31, 2010.
86. Kircik L. A Nonsteroidal Lamellar Matrix Cream Containing Palmitoylethanolamide for the Treatment
of Atopic Dermatitis. J Drugs Dermatol. 2010;9(4):334–338.
87. Abramovits W, Gover MD, Gupta AK. Atopiclair Nonsteroidal Cream. Skinmed. 2005;4(6):369.
88. Jacob S, Breithaupt A. Environmental Exposures — A Pediatric Perspective on Allergic Contact Dermatitis.
Skin & Aging. 2009;17(7):28–36.
89. Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and
cross-reactivity. J Am Acad Dermatol. 2006;54(4):723–727.
90. External Agents, Emulsifiers. Allergeaze website. Available at: http://www.allergeaze.com/
allergens.aspx?ID=EE. Accessed August 31, 2010.
10 Januar y 2011 ◆ Supplement to Skin & Aging